Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sida 1 från 25 resultat
Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tyrptophan and possibly a vitamin B12 compound
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This invention relates to the treatment of Multiple Sclerosis (MS) and other Demyelinating Conditions.
Multiple sclerosis is a common and well known neurological disorder. It is characterised by episodic patches of inflammation and demyelination which can occur anywhere in the central nervous system
Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This invention relates to the treatment of Multiple Sclerosis (MS) and other Demyelinating Conditions.
Multiple sclerosis is a common and well known neurological disorder. It is characterised by episodic patches of inflammation and demyelination which can occur anywhere in the central nervous system
Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
The present invention relates to a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment
Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a
Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a
Treatment of tuberous sclerosis associated neoplasms
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention relates to a new use of PDGF receptor tyrosine kinase inhibitors or bcr-abl receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula I (hereinafter: "COMPOUNDS of formula I") in which the symbols and substituents have the meaning as
Treatment of multiple sclerosis with masitinib
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention relates to the treatment of multiple sclerosis (MS). The present invention relates to the administration of masitinib in an appropriate dosage regimen, and in particular in the treatment of MS.
BACKGROUND OF THE INVENTION
Multiple Sclerosis
Multiple Sclerosis (MS) is a common
Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a
Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention describes a series of new compounds that display potent inhibition against Bruton's tyrosine kinase and, therefore, may provide a potential therapeutic approach to treating human cancers including B-cell lymphoma, and autoimmune diseases such as rheumatoid
Process for the preparation of copolymer-1 using a polymer supported dialkylamine initiator
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This application is a 371 of PCT/IN2009/000320, filed Jun. 4, 2009.
FIELD OF THE INVENTION
The present invention relates to a process for the synthesis of Copolymer-1 (Cop I). composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine for the treatment of multiple sclerosis.
BACKGROUND AND
Treatment of eosinophil or mast cell related disorders
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This application incorporates by reference a Sequence Listing submitted with this application as text file entitled "Sequence_Listing_12638-123-228.TXT" created on May 21, 2015 and having a size of 21,490 bytes.
1. FIELD
Provided herein are methods and uses involving antibodies that specifically
Inhibitors of C-FMS kinase
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase.
Protein kinases are enzymes that serve as key components of signal
Methods of treating disease with random copolymers
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
An autoimmune disease results from an inappropriate immune response directed against a self antigen (an autoantigen), which is a deviation from the normal state of self-tolerance. Self-tolerance arises when the production of T cells and B cells capable of reacting against
Methods of treating disease with random copolymers
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
An autoimmune disease results from an inappropriate immune response directed against a self antigen (an autoantigen), which is a deviation from the normal state of self-tolerance. Self-tolerance arises when the production of T cells and B cells capable of reacting against
Copolymers for suppression of autoimmune diseases, and methods of use
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The invention relates to design of copolymers having particular amino acids in specific molar ratios, synthesized into polypeptides of predetermined length and capable of suppression of symptoms and frequency of recurrent episodes of an autoimmune disease.
BACKGROUND
Multiple
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
